{"id":30667,"date":"2016-10-01T09:07:58","date_gmt":"2016-10-01T09:07:58","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=30667"},"modified":"2016-10-03T17:09:15","modified_gmt":"2016-10-03T17:09:15","slug":"single-pill-pi-based-combination-submitted-to-ema","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/30667","title":{"rendered":"Single-pill PI-based combination submitted to EMA"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 12 September 2016, a press statement from Janssen reported that the company have submitted an application to the European Medicine Agency (EMA) for a single pill PI-based combination.<\/strong><\/p>\n<p>This formulation includes darunavir (800 mg), cobicistat (150mg), emtricitabine (200 mg) and tenofovir alafenamide (10 mg). Tenofovir alafenamide (TAF) is the new version of tenofovir- DF.<\/p>\n<p>The indication is for treatment of adults and adolescents (aged 12 years and older with body weight of at least 40 kg).<\/p>\n<h3>Comment<\/h3>\n<p><strong>The potential benefits of this new formulation will depend on it being priced comparable to a combination with the NRTI component being similar to generic alternatives.<\/strong><\/p>\n<p>Reference:<\/p>\n<p>Janssen Submits Marketing Authorisation Application for Darunavir-Based Single Tablet Regimen for Treatment of HIV-1 to European Medicines Agency. (12 September 2016).<br \/>\n<a href=\"http:\/\/www.janssen.com\/janssen-submits-marketing-authorisation-application-darunavir-based-single-tablet-regimen-treatment\">http:\/\/www.janssen.com\/janssen-submits-marketing-authorisation-application-darunavir-based-single-tablet-regimen-treatment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 12 September 2016, a press statement from Janssen reported that the company have submitted an application to the European Medicine Agency (EMA) for a single pill PI-based combination. This formulation includes darunavir (800 mg), cobicistat &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-30667","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=30667"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30667\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=30667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=30667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=30667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}